What Amgen Bulls Got Right

If you only skimmed the headlines about Tavneos scrutiny, product recalls and court fights over Enbrel pricing, Amgen might have looked like trouble, not opportunity. Investors who held Amgen over the past year are up 44.4%, including dividends. If you had been deciding on 13 October 2025 with only the aging blockbusters debate and the bullish chronic-care story in front of you, what made that call so hard?

The move put Amgen in the middle of this trade. Scan 33 healthcare AI stocks for other companies exposed to it.

The Two Amgen Stories Investors Had To Hold In Their Heads

The shares cost US$292 at the start of the period, and Amgen holders were weighing two sharply different stories about what came next.

On the optimistic side, the bullish narrative put Fair Value at US$403. This price was implied by assumptions about Amgen expanding chronic care markets through biosimilars and targeted therapies, backed by volume-led sales growth and AI-enabled R&D.

The bearish view set Fair Value at US$185. This outlook was built on concerns that Enbrel and other aging blockbusters would face pricing pressure, patent expiries, and rising biosimilar competition that could erode margins.

What The Results Changed In The Amgen Argument

Amgen’s Q2 2026 numbers did real work on those 2025 stories. Revenue moved from US$9.18b in Q2 2025 to US$10.05b, while net income rose from US$1.43b to US$2.38b and net margin improved from 15.6% to 23.6%. That mix of higher sales and higher profitability supported the optimistic case about volume strength and margin potential, even as Tavneos scrutiny and recalls kept regulatory risk in view.

The takeaway is simple. When a thesis hangs on margin resilience versus pricing and patent pressure, treat net margin as the central figure and track it quarter by quarter against each side of the story.

What Amgen’s Price Seems To Be Saying Now

Amgen now trades at US$413. The selected Narrative argues that its Fair Value sits below that level because it sees policy pressure, biosimilar rivalry and big 2026 capex as possible drags on earnings power.

At this price you are effectively assuming newer cardiometabolic, autoimmune, oncology and biosimilar franchises more than cover older patent losses. How does that square with the Narrative’s concern about pricing pressure and under earning new capacity?

"The rapid expansion of the 340B discount program, with purchases at approximately US$100b and discounts of about US$80b, raises the risk that an increasing share of Amgen’s U.S. hospital volume flows through channels with structurally lower net pricing. This may weigh on net margins and limit future EPS growth even if top-line volumes rise."

One Narrative disagrees with today's price. → See where this Narrative says Amgen should trade

Another Healthcare Engine To Watch

Amgen pulls you into tough questions about drug pricing and patent risk. Nearby, another major healthcare group faces similar pressures.

Instead of biologic arthritis workhorses, this business spreads its effort across prescription treatments and surgical tools.

That mix spans cancer, immune conditions, brain disorders and heart care. Research projects and acquisitions aim to refresh the overall portfolio.

New medicines, complex therapies and advanced surgical systems all sit inside that plan.

Legal disputes, pricing reforms and higher fixed costs still hang over it, leaving how this broad engine handles those headwinds an open question.

One Narrative has already put a figure on it. → Uncover the company trading 22% below one Narrative's Fair Value

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com